ClinicalTrials.gg
Status unknownNCT04520945Updated Aug 20, 2020

Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis

A Phase 2 interventional study of Chondrogen and Placebo in Osteoarthritis, Knee, sponsored by Meluha Life Sciences SDN BHD. Status unknown at 1 site in Malaysia. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Meluha Life Sciences SDN BHD · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Study summary

Primary osteoarthritis is a debilitating disease characterized by extensive damage to the joints and excruciating pain leading to loss of activity and depression. Despite advances in diagnosis, the quest for the development of a disease-modifying osteoarthritis drug has proven unsuccessful. Human cartilage only has limited regenerative potential. Transplantation is a promising strategy given the high proliferative capacity of MSCs and their potential to differentiate into cartilage-producing cells - chondrocytes. The acquisition of MSC does not require invasive surgical intervention or cartilage extraction from other sites as required by other cell-based strategies. The investigators inject allogeneic human mesenchymal stem cells to the cartilage lesions in patients via intra-articular injection method, and to investigate the efficacy and safety.

Read the detailed description

Osteoarthritis is one of the commonest diseases in the world, with a global disease burden of 83%. Plain radiograph remained the main modality in diagnosing osteoarthritis. Chondrogen is a mesenchymal stem cell-derived from umbilical cord tissue product. The mesenchymal stem cell is used for the study because of its ability to proliferate and differentiate into various tissues such as chondrocytes, adipocytes, and osteocytes. Various clinical studies have been conducted for arthritis, orthopedic, joint, and cartilage.

This study will enroll 100 patients age 30-70 years old. They will be divided into 2 groups which are the group which will receive the investigational drug (ChondrogenTM and HA) and another group will receive a placebo (saline and HA). It will be a randomized double-blinded study where the participants and the investigator would not know what are the things being received. This study will be conducted for 24 months. The injection will be given on the baseline day after screening the volunteers. The patients will be assessed on VAS, WOMAC, IKDC, KOOS PROMIS29, the interleukins, and MRI.

02

Conditions studied

  • Osteoarthritis, Knee
03

In context

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 100 is above the median of 68 across 2,716 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

This is the only study on the registry with Meluha Life Sciences SDN BHD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30-70 years old
  • No serious infection, chronic diseases, diabetes and tuberculosis
  • Idiopathic or secondary osteoarthritis of the knee with grade 1-3 defined by the modified Kellgren-lawrence classification
  • Written informed consents were obtained from all subjects.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Women of unwilling to use two forms of
  • Cognitively impaired adults
  • Presence of large meniscal tears
  • Inflammatory or post-infectious arthritis
  • More than 5 degrees of varus or valgus deformity
  • Kellgren Lawrence grade 4 osteoarthritis in two compartments in persons over 60 years of age
  • Intra-articular injection within the 3 previous months
  • Major neurologic deficit
  • Arthroscopy during the previous 6 months
  • Poorly controlled diabetes mellitus
  • or anticoagulant treatment
  • NSAID therapy within 15 days prior to inclusion in the study
  • Serious medical illness with a of less than 1 year
  • Prior admission for substance abuse
  • (BMI) of 40 kg/m2 or greater
  • Patient receiving experimental medication or participating in another clinical study within 30 days of signing the
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Active Participant of Phase 2B Clinical Study Chondrogen

    50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.

    Biological: Chondrogen

  • Placebo comparator
    Placebo Participant of Phase 2B Clinical Study Chondrogen

    50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.

    Biological: Placebo

Interventions

  • BiologicalChondrogen

    Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid

    Also known as: Mesenchymal Stem Cell

  • BiologicalPlacebo

    Consist of saline and hyaluronic acid

06

What researchers measure

Primary outcomes

  1. VAS score

    Change from Baseline in Visual Analogue Scale (VAS)

    Time frame: 12 months

  2. WOMAC score

    Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index Score (WOMAC)

    Time frame: 12 months

  3. IKDC score

    Change from Baseline in knee function change and improvement (IKDC)

    Time frame: 12 months

  4. KOOS score

    Change from Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: 12 months

Secondary outcomes

  1. PROMIS29 score

    Change in Patient-Reported Outcomes Measurement Information System (PROMIS29) scores

    Time frame: 12 months

  2. Kellegren-Lawrence grading

    Number of participants evaluated by X-ray and MRI of knee OA from baseline Kellegren-Lawrence grading system.

    Time frame: 12 months

  3. Interleukins

    Changes of interleukins (IL-1b, IL-6, PGE-2, TGF-b, TNF-a, IGF-1) of articular cavity fluid from baseline to week 12

    Time frame: 12 months

07

Study locations

1 site
  • Department of Orthopedic & Traumatology, Faculty of Medicine, Hospital Canselor Tuanku Mukhriz, UKM Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur.
    Cheras, Kuala Lumpur 56000, Malaysia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2020; primary completion for Sep 2021, 10 months later.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 10 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2020
First posted
Aug 20, 2020
StartEst.
Oct 31, 2020
Primary completionEst.
Sep 30, 2021
CompletionEst.
Sep 30, 2022
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04520945
Lead sponsor
Meluha Life Sciences SDN BHD
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Oct 31, 2020 (estimated)
Primary completion
Sep 30, 2021 (estimated)
Completion
Sep 30, 2022 (estimated)
Last update
Aug 20, 2020

Study contacts

Prakash Nathan, MBA
Contact
research@meluhalifesciences.com
03-88902968
Raisah Hadi, MSC
Contact
research@meluhalifesciences.com
03-88902968 ext. 105
Badrul Akmal Hisham, MBBS
principal investigator · PPUKM

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesenchymal Stem Cell

Start the discussion